Table 1.

Antiestrogen use and incidence of RA and SLE in patients with breast cancer.

RASLE
DrugMos of TreatmentTotal PatientsNRate, %OR (95% CI)NRate, %OR (95% CI)
None0190,62044602.341.00 (ref)13300.701.00 (ref)
SERM2–1111,1803302.951.26*** (1.13–1.41)1100.981.41*** (1.16–1.71)
12+1420805.632.41*** (1.92–3.02)201.412.02** (1.29–3.15)
AI2–1120,4206303.091.32*** (1.21–1.44)1200.590.84 (0.70–1.02)
12+37001604.321.85*** (1.57–2.17)200.540.77 (0.50–1.21)
  • Statistically significant at

  • ** p < 0.01,

  • *** p < 0.001.

  • SERM: selective estrogen receptor modulator; AI: aromatase inhibitor; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus.